South Dakota Clinical Trials Report — June 2026

For South Dakotans considering participation in clinical research, June 2026 presents both urgent opportunities and promising new avenues. A critical window is closing for 9 clinical trials statewide, which are slated to conclude within the next 90 days. This includes 4 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition before these opportunities vanish.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various conditions, from skin health to cancer, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Atopic dermatitis
• Brain health
• Breast cancer
• Breast cancer screening
• Breast carcinoma in situ
• Cardiometabolic health
• Chronic granulomatous disease (CGD)
• Cognitive decline prevention in robust older adults
• COVID-19
• Dry eye disease (DED)

New Research Horizons: Spotlight on June's Openings

This month, South Dakota welcomes 3 new clinical trials, maintaining a consistent pace of research activity compared to the 4 trials that opened in May 2026. These new studies include a significant Phase IIIb drug trial from a major pharmaceutical company, offering participants access to cutting-edge treatments for a widespread health challenge.

A notable addition is NCT07647328, "A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer." Sponsored by AstraZeneca, this important drug trial aims to enroll 150 participants. The study's purpose is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib for patients with ER-positive, HER2-negative breast cancer who have not yet received other systemic treatments for advanced disease. Participants will continue treatment within the trial until discontinuation, providing a long-term treatment option for eligible individuals.

Beyond this significant cancer study, other new trials opening this month address a range of conditions, reflecting diverse research interests across the state. These new opportunities include studies focused on:

• Brain health
• Cardiometabolic health
• Cognitive decline prevention in robust older adults
• Dry eye disease (DED)
• Dry eye syndrome (DES)
• Healthy aging
• Normal aging

Of the 3 new trials, 2 are drug trials, indicating a focus on testing new therapeutic compounds. The remaining study falls under the 'OTHER' intervention type, suggesting research into diagnostics, procedures, or behavioral interventions.

Contributing to Health: Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. Of the 3 new trials launched this month, 1 is actively seeking healthy volunteers. This adds to the existing opportunities, bringing the total number of trials currently recruiting healthy participants statewide to 20. These studies are crucial for establishing baseline data and understanding health processes in individuals without specific conditions.

As mentioned, 4 of the trials closing within the next 90 days also accept healthy volunteers. This means that individuals interested in contributing to research without a specific diagnosis should explore these options promptly before enrollment closes.

South Dakota's Research Footprint: Where to Participate

South Dakota's clinical research landscape continues to be active, with 331 clinical trials currently recruiting across 16 cities and 146 research sites statewide. This broad distribution ensures that residents in various regions of South Dakota have access to cutting-edge research opportunities.

This month, new research initiatives are concentrated in two key locations:

• Sioux Falls (2 new trials)
• Brookings (1 new trial)

Sioux Falls, as a major population center, continues to be a hub for clinical investigations, while Brookings also demonstrates a commitment to expanding research access. This geographic spread allows for greater participation and ensures that research findings are relevant to a diverse population within the state.

A Look Ahead: Sustaining Research Momentum

The clinical trials opening in June 2026 reflect a commitment to addressing significant health challenges, from advanced breast cancer to various aspects of aging and general health. All 3 new trials include older adults, highlighting a focus on research relevant to this demographic. Academic institutions, such as South Dakota State University, and specialized centers like Vance Thompson Vision, alongside industry leaders like AstraZeneca, are driving these important research efforts.

As we move through June, the focus will remain on the ongoing enrollment in these significant studies and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across South Dakota.